Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.52 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.52 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.52 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.52 |
| ▸ | P2RY2 | P41231 | 13/20 | 0.47 |
| ▸ | P2RY6 | Q15077 | 9/20 | 0.47 |
| ▸ | P2RY4 | P51582 | 4/20 | 0.46 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL154356 | 0.82 | SLC28A1 (0.60) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL4296321 | 0.81 | SLC28A1 (0.55) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL8588530 | 0.81 | SLC28A1 (0.56) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL4543043 | 0.81 | SLC28A1 (0.56) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL3968336 | 0.81 | PYGM (0.54) | P2RY2P2RY6P2RY4 | |
| SCHEMBL629553 | 0.80 | DUT (0.45) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL5846581 | 0.79 | SLC28A1 (0.63) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL8201123 | 0.78 | SLC28A1 (0.62) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL4950152 | 0.78 | SLC28A1 (0.61) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL1696779 | 0.78 | SLC28A1 (0.61) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1992014758-A1 | CONJUGATE MOLECULES | THE AUSTIN RESEARCH INSTITUTE (AU) | 1992-09-03 | — | — | WO | claimed |
| EP-1305296-B9 | 5-SUBSTITUTED PYRIMIDINE DERIVATIVES OF CONFORMATIONALLY LOCKED NUCLEOSIDE ANALOGUES | US GOV HEALTH & HUMAN SERV (US) | 2010-04-07 | — | — | EP | disclosed |
| EP-1305296-B1 | 5-SUBSTITUTED PYRIMIDINE DERIVATIVES OF CONFORMATIONALLY LOCKED NUCLEOSIDE ANALOGUES | US GOV HEALTH & HUMAN SERV (US) | 2009-09-09 | — | — | EP | disclosed |
| EP-2054406-A1 | NUCLEOSIDES FOR SUPPRESSING OR REDUCING THE DEVELOPMENT OF RESISTANCE IN CYTOSTATIC THERAPY | RESprotect GmbH (DE) | 2009-05-06 | — | — | EP | disclosed |
| WO-2008017515-A1 | NUCLEOSIDES FOR SUPPRESSING OR REDUCING THE DEVELOPMENT OF RESISTANCE IN CYTOSTATIC THERAPY | RESPROTECT GMBH (DE) | 2008-02-14 | — | — | WO | disclosed |
| US-20070202115-A1 | Preparation for the prevention and/or treatment of a tissue change of mesenchymal origin | BULLERDIEK JORN | 2007-08-30 | — | — | US | disclosed |
| US-7009050-B2 | 5-Substituted pyrimidine derivatives of conformationally locked nucleoside analogues | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2006-03-07 | — | — | US | disclosed |
| US-20050282837-A1 | 5-SUBSTITUTED PYRIMIDINE DERIVATIVES OF CONFORMATIONALLY LOCKED NUCLEOSIDE ANALOGUES | GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, THE | 2005-12-22 | — | — | US | disclosed |
| EP-1305296-A2 | 5-SUBSTITUTED PYRIMIDINE DERIVATIVES OF CONFORMATIONALLY LOCKED NUCLEOSIDE ANALOGUES | The Government of the United States of America, as represented by the Secretary Department of Health and Human Services (US) | 2003-05-02 | — | — | EP | disclosed |
| WO-2002008204-A2 | 5-SUBSTITUTED PYRIMIDINE DERIVATIVES OF CONFORMATIONALLY LOCKED NUCLEOSIDE ANALOGUES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2002-01-31 | — | — | WO | disclosed |
| WO-1992014758-A1 | CONJUGATE MOLECULES | THE AUSTIN RESEARCH INSTITUTE (AU) | 1992-09-03 | — | — | WO | disclosed |
| EP-0233493-A2 | Process for producing ribonucleosides | Yamasa Shoyu Kabushiki Kaisha (JP) | 1987-08-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282837-A1 | 5-SUBSTITUTED PYRIMIDINE DERIVATIVES OF CONFORMATIONALLY LOCKED NUCLEOSIDE ANALOGUES | TYMP, DPYD, TYMS | SLC28A1 84/4885SLC28A2 82/4885SLC29A1 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.